冠状动脉支架市场－2024年至2029年预测

2022年冠状动脉支架市场估值为92.6亿美元。

在冠状动脉中放置一种可扩张的管状金属植入，称为冠状动脉支架 (CS)，由于潜在的动脉粥状硬化而使用。这种重组手术称为经皮冠状动脉介入治疗 (PCI) 或冠状动脉支架置放术。此外，冠状动脉支架的可扩张金属网膜可减少有害的重塑、冠状动脉夹层和血管反冲。

冠状动脉支架市场的驱动因素

推动冠状动脉支架需求的主要因素是心臟病盛行率的增加。随着糖尿病、高血压和肥胖等疾病的盛行率不断增加，冠状动脉心臟病在全球变得越来越常见。随着人口老化，预计需要更多的冠状动脉支架。由于该领域技术的发展，冠状动脉支架市场正在不断成长。这些新设备改善的患者治疗效果、安全性和有效性推动了冠状动脉支架市场的成长。

冠状动脉疾病盛行率上升

根据美国国家医学图书馆 2021 年 6 月发表的一项研究，冠状动脉疾病是美国的首要死因，每年造成约 61 万人死亡。因此，由于 CAD 发生率空前上升，对有效冠状动脉支架技术的需求预计将会成长。预计此因素将在预测期内维持需求。由于冠状动脉支架用于大多数经皮冠状动脉介入治疗（PCI）手术，因此冠状动脉支架市场预计将扩大。

扩展 DES 的日益普及

与传统的球囊血管成形术相比，增强型 DES 和生物可吸收支架的发展提高了支架留置技术的普及度。冠状动脉支架的技术进步，例如双支架的发明和生物分解性材料的使用，提高了CVD治疗的有效性和结果。上述因素可能会在整个预测期内推动冠状动脉支架市场的成长。

加大医疗保健投资

美国卫生与公众服务部医疗保险与医疗补助服务中心预测，2021 年美国医疗保健支出将成长 2.7%，达到 4.3 兆美元。随着医疗费用的增加，更多的患者将能够接受支架置入治疗，从而刺激冠状动脉支架市场的成长。此外，政府和私人公司的优惠报销政策正在为更多人提供支架置入治疗，这推动了需求。

BMS支架越来越受欢迎

由于新技术的进入障碍较低，且临床证据证明了 BMS 的优越性，BMS 支架持续成长。 BMS 支架类型因其实惠的设备价格而能够保持其在冠状动脉支架市场的地位。由于其低成本和低住院率，BMS 被用于许多 PCI 手术中，儘管 DES 的改进已经取代了它的使用。继DES之后，生物可吸收支架（BRS）是市场上出现的最新技术。

技术进步

由于多项技术进步使冠状动脉支架行业具有吸引力，预计冠状动脉支架的需求将在预测期内显着增加。持续的研究和开发导致了第一个完全可溶解支架的开发。这些支架刚刚获得 FDA 批准进入冠状动脉支架市场，用于大多数心血管手术。随着冠状动脉疾病的增加，对这些治疗的需求可能会增加。

北美冠状动脉支架市场预计将逐步扩大。

冠状动脉支架技术的技术进步，如药物释放型支架和生物分解性材料的使用，正在进一步加速冠状动脉支架市场的扩张。在冠状动脉支架产业中，亚太地区预计收益将成长最快。冠状动脉支架市场也受到 CAD筛检加强、经济成长、监管更新以及一些国家高度优惠的报销等原因的推动。此外，该产业也受到政府对医疗保健投资增加以及印度和中国等成本受限地区降低产品价格的新措施的影响。

主要市场参与者的策略

在全球冠状动脉支架市场中，雅培（Abbott）实验室、波士顿科学（Boston Scientific）和美敦力（Medtronic）凭藉在利润丰厚的 DES 市场上的良好记录以及包括各种不同类型 IC 设备的广泛产品系列而拥有强大的影响力。我是。这些公司在业界占有重要地位。儘管三大厂商占据主导地位，但国内外已有多家企业进入冠脉支架产业。例如，百多力透过提供实惠的价格和填补冠状动脉支架市场空白的最尖端科技，建立了强大的影响力。

目录

第一章简介

• 市场概况
• 市场定义
• 调查范围
• 市场区隔
• 货币
• 先决条件
• 基准年和预测年时间表

第二章调查方法

• 调查资料
• 先决条件

第三章执行摘要

• 研究亮点

第四章市场动态

• 市场驱动因素
• 市场限制因素
• 波特五力分析
• 产业价值链分析

第五章冠状动脉支架市场：依类型

• 介绍
• 裸金属支架
• 药物释放型支架
• 生物可吸收支架

第六章冠状动脉支架市场：依交付模式

• 介绍
• 球囊扩张型支架
• 自动扩张型支架

第七章冠状动脉支架市场：依最终用户分类

• 介绍
• 医院
• 心臟中心
• 门诊手术中心

第八章冠状动脉支架市场：按地区

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
• 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 其他的
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章竞争环境及分析

• 主要企业及策略分析
• 市场占有率分析
• 合併、收购、协议和合作

第十章 公司简介

• SLTL Medical
• Boston Medical
• Amg International
• Translumina Therapeutics
• Arterius
• Medtronic
• Abbott Vascular
• SMTPL
• Integer Holdings
• Relisys Medical Devices

The coronary stent market was valued at US$9.26 billion in 2022.

The placement of expandable tubular metallic implants called coronary stents (CS) into coronary arteries that have been used due to the underlying atherosclerotic disease. This revascularization procedure is known as percutaneous coronary intervention (PCI) or coronary angioplasty with stent placement. Additionally, due to the expandable, metallic meshwork of coronary stents, which inhibits adverse remodeling, coronary dissection, and vascular recoil have been removed.

Driving factors for the coronary stents market

The growing incidence of heart disease is the primary factor driving the need for coronary stents. With the increasing prevalence of diseases including diabetes, hypertension, and obesity, CAD is becoming more common globally. As the population ages, more coronary stents are expected to be required. The coronary stent market is growing as a result of technological developments in the field. The improved patient outcomes, safety, and efficacy of these novel devices are what is driving the coronary stent market growth.

Rising prevalence of coronary artery disease

In the US, coronary artery disease, is the leading cause of death, accounting for about 610,000 fatalities yearly according to research published in the National Library of Medicine in June 2021. The need for effective coronary stent technology is thus expected to expand as a result of the unprecedented rise in CAD incidence. This factor is expected to sustain demand during the forecast timeframe. Since most Percutaneous Coronary Intervention (PCI) operations involve the use of a coronary stent, the coronary stent market is expected to grow.

Growing popularity for enhanced DES

Enhanced DES and the creation of bioresorbable scaffolds have increased the popularity of stenting technology relative to conventional balloon angioplasty. The efficacy and outcomes of treating CVD have improved due to technical advancements in coronary stents, such as the invention of bifurcation stents and the use of biodegradable materials. The aforementioned elements are likely to drive coronary stent market growth throughout the forecast period.

Increasing investment in healthcare

The Centres for Medicare & Medicaid Services of the United States Department of Health and Human Services estimate that U.S. healthcare spending will increase 2.7 percent in 2021 to reach $4.3 trillion. More patients can obtain stent installation treatments as healthcare spending rises, fueling coronary stent market growth. Additionally, more people have access to stent installation treatments because of favorable reimbursement policies from governments and private insurance companies, which is fueling demand.

Rising popularity for BMS stents

BMS stents continue to grow due to low entry hurdles for new technologies and clinical evidence showing BMS's advantages. The BMS stent type can keep its position in the coronary stent market because of its affordable device price. BMS is utilized in many PCI procedures despite the improvement in DES replacing its use because of its inexpensive cost and low hospitalization rates. After DES, bioresorbable scaffolds (BRS) are the most recent technology to hit the market.

Advancement in technology

Demand for coronal stents is expected to rise considerably throughout the projection period due to several technical advancements that have made the coronary stent industry appealing. Continuous research and development led to the first completely dissolving stents. These stents, which were just introduced to the coronary stent market after receiving FDA permission, are utilized in the majority of cardiac operations. There will be a higher need for these therapies as incidences of coronary artery disease rise.

The market for coronary stents is expected to expand gradually in North America.

Technical advancements in coronary stent technologies, such as drug-eluting stents and the use of biodegradable materials, have further sped up the expansion of the coronary stent market. Asia Pacific is expected to see the fastest revenue growth in the coronary stent industry. The market for coronary stents is also driven by other reasons including enhanced CAD screening, economic growth, regulatory updates, and very favorable reimbursement in some countries. Additionally, this industry is being impacted by growing government investment in healthcare and new attempts to provide products at cheap costs in cost-constrained regions like India and China.

Key market player strategies

In the global coronary stent market, Abbott Laboratories, Boston Scientific, and Medtronic had a large presence due to their outstanding performance in the lucrative DES market and their extensive product portfolios, which include a wide range of various IC device types. These businesses have established a noticeable presence in the industry. Despite the three main manufacturers' dominance, there are several national and international participants in the coronary stent industry. By providing affordable prices and cutting-edge technologies that fill gaps in the coronary stent market, BIOTRONIK, for instance, has been able to build a sizable presence.

Market Key Developments

• In April 2023, leading medical device firm Terumo Europe N.V. started a new prospective clinical research using the Ultimaster NagomiTM sirolimus-eluting coronary stent system in patients undergoing difficult PCI to further product and patient care innovation.
• In August 2022, Medtronic introduced the Onyx Frontier drug-eluting stent in Europe.
• In July 2022, the unique Pulsar®-18 T3 peripheral self-expanding stent system from BIOTRONIK was approved by the U.S. Food and Drug Administration (FDA) for a better insertion method during endovascular treatments, the company stated.

Segmentation:

By Type

• Bare-metal Stents
• Drug-eluting Stents
• Bioabsorbable Stents

By Delivery Mode

• Balloon-expandable Stents
• Self-expanding Stents

By End-User

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. CORONARY STENT MARKET, BY TYPE

• 5.1. Introduction
• 5.2. Bare-metal Stents
• 5.3. Drug-eluting Stents
• 5.4. Bioabsorbable Stents

6. CORONARY STENT MARKET, BY DELIVERY MODE

• 6.1. Introduction
• 6.2. Balloon-expandable Stents
• 6.3. Self-expanding Stents

7. CORONARY STENT MARKET, BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Cardiac Centers
• 7.4. Ambulatory Surgical Centers

8. CORONARY STENT MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

• 10.1. SLTL Medical
• 10.2. Boston Medical
• 10.3. Amg International
• 10.4. Translumina Therapeutics
• 10.5. Arterius
• 10.6. Medtronic
• 10.7. Abbott Vascular
• 10.8. SMTPL
• 10.9. Integer Holdings
• 10.10. Relisys Medical Devices